Evaluation of metabolic biochemical parameters in complicated cases of type 1 and type 2 diabetes mellitus
References
- Banday MZ, Sameer AS, Nissar S. Pathophysiology of diabetes: An overview. Avicenna J Med. 2021; 10:174–88.
- Magliano DJ, Boyko EJ, Committee IDA 10th edition scientific. Global picture. In: IDF Diabetes Atlas [Internet]. 10th ed. Brussels: International Diabetes Federation; 2021 [cited 2024 Oct 14]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK581940/
- Magliano DJ, Boyko EJ, Committee IDA 10th edition scientific. IDF Diabetes Atlas [Internet]. 10th ed. Brussels: International Diabetes Federation; 2021 [cited 2024 Oct 14]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK581934/
- GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023; 402(10397):203–34.
- Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022; 400(10365):1803–20.
- Ozougwu JC. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. J Physiol Pathophysiol. 2013; 4(4):46–57.
- Mauricio D, Alonso N, Gratacos M. Chronic Diabetes Complications: The Need to Move beyond Classical Concepts. Trends Endocrinol Metab. 2020; 31(4):287–95.
- Shamshirgaran SM, Mamaghanian A, Aliasgarzadeh A, Aiminisani N, Iranparvar-Alamdari M, Ataie J. Age differences in diabetes-related complications and glycemic control. BMC Endocr Disord. 2017; 17(1):25.
- Bonora E, Trombetta M, Dauriz M, Travia D, Cacciatori V, Brangani C, et al. Chronic complications in patients with newly diagnosed type 2 diabetes: prevalence and related metabolic and clinical features: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 9. BMJ Open Diabetes Res Care. 2020; 8(1):e001549.
- Aikaeli F, Njim T, Gissing S, Moyo F, Alam U, Mfinanga SG, et al. Prevalence of microvascular and macrovascular complications of diabetes in newly diagnosed type 2 diabetes in low-and-middle-income countries: A systematic review and meta-analysis. PLOS Glob Public Health. 2022; 2(6):e0000599.
- Gedebjerg A, Almdal TP, Berencsi K, Rungby J, Nielsen JS, Witte DR, et al. Prevalence of micro- and macrovascular diabetes complications at time of type 2 diabetes diagnosis and associated clinical characteristics: A cross-sectional baseline study of 6958 patients in the Danish DD2 cohort. J Diabetes Complications. 2018; 32(1):34–40.
- American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021; 44(Suppl 1):S15–33.
- Fan L, Wu XJ. Sex difference for the risk of amputation in diabetic patients: A systematic review and meta-analysis. PLoS One. 2021; 16(3):e0243797.
- Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018; 17(1):83.
- Goldsweig AM, Knee A, Tak HJ, Desai NR, Bradley SM, Lotfi AS, et al. Cardiovascular Event Prevalence in Type 1 Versus Type 2 Diabetes: Veradigm Metabolic Registry Insights. J Soc Cardiovasc Angiogr Interv [Internet]. 2025; 4(3). [cited 2025 Apr 10]. Available from: https://www.jscai.org/article/S2772-9303(24)02191-4/fulltext
- Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy. Diabetes Care. 2012; 35(3):556–64.
- Leeds JS, Forman EM, Morley S, Scott AR, Tesfaye S, Sanders DS. Abnormal liver function tests in patients with Type 1 diabetes mellitus: prevalence, clinical correlations and underlying pathologies. Diabet Med. 2009; 26(12):1235–41.
- Mantovani A, Byrne CD, Targher G. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Curr Diab Rep [Internet]. [cited 2025 Apr 17]. Available from: https://link.springer.com/article/10.1007/s11892-021-01383-7
- Tilg H, Moschen AR, Roden M. The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments. Nat Rev Gastroenterol Hepatol [Internet]. [cited 2025 Apr 17]. Available from: https://www.nature.com/articles/s41575-021-00448-y
- Chandrasekaran P, Weiskirchen R. The Role of Obesity in Type 2 Diabetes Mellitus—An Overview. Int J Mol Sci. 2024; 25(3):1882.
- Campos A, Gutierrez RR, Galindo RJ, McCoy RG, Hurtado Andrade MD. Managing obesity in adults with type 1 diabetes. Diabetes Res Clin Pract. 2025; 220:111983.
- Feingold KR. Obesity and Dyslipidemia. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 [cited 2025 Apr 11]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK305895/
- Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009; 32(9):1737–42.
- Jiang Z, Wang Y, Zhao X, Cui H, Han M, Ren X, et al. Obesity and chronic kidney disease. Am J Physiol Endocrinol Metab. 2023; 324(1):E24–41.
- El Meouchy P, Wahoud M, Allam S, Chedid R, Karam W, Karam S. Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control. Int J Mol Sci. 2022; 23(20):12305.
- Katta N, Loethen T, Lavie CJ, Alpert MA. Obesity and Coronary Heart Disease: Epidemiology, Pathology, and Coronary Artery Imaging. Curr Probl Cardiol. 2021; 46(3):100655.
- Sattar N, Neeland IJ, McGuire DK. Obesity and Cardiovascular Disease: A New Dawn. Circulation. 2024; 149(21):1621–3.
- Tabassum S, Azhar F, Hussain F, Naeem A, Sheffeh MA, Asghar MS. Trends in ischemic heart disease-related mortality in obese population in the United States. Cardiovasc Endocrinol Metab. 2025; 14(2):e00325.
- Cheung BMY, Li C. Diabetes and Hypertension: Is There a Common Metabolic Pathway? Curr Atheroscler Rep. 2012; 14(2):160–6.
- Jia G, Sowers JR. Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease. Hypertension. 2021; 78(5):1197–205.
- Brath H, Kaser S, Tatschl C, Fischer-See S, Fasching P. Smoking, heated tobacco products, alcohol and diabetes mellitus (update 2023). Wien Klin Wochenschr. 2023; 135(Suppl 1):84–90.
- Lu T, Nakanishi T, Yoshiji S, Butler-Laporte G, Greenwood CMT, Richards JB. Dose-dependent Association of Alcohol Consumption With Obesity and Type 2 Diabetes: Mendelian Randomization Analyses. J Clin Endocrinol Metab. 2023; 108(12):3320–9.
- Azagew AW, Mekonnen CK, Lambie M, Shepherd T, Babatunde OO. Poor glycemic control and its predictors among people living with diabetes in low- and middle-income countries: a systematic review and meta-analysis. BMC Public Health. 2025; 25(1):714.
- Zhang Z, Ma L, Geng H, Bian Y. Effects of Smoking, and Drinking on Serum Gamma-Glutamyl Transferase Levels Using Physical Examination Data: A Cross-Sectional Study in Northwest China. Int J Gen Med. 2021; 14:1301–9.
- Ho FK, Ferguson LD, Celis-Morales CA, Gray SR, Forrest E, Alazawi W, et al. Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes: A prospective cohort study in the UK Biobank. eClinicalMedicine [Internet]. 2022;48. [cited 2025 Apr 17]. Available from: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00165-1/fulltext
DOI: https://doi.org/10.2478/orvtudert-2025-0001 | Journal eISSN: 2537-5059 | Journal ISSN: 1453-0953
Language: English
Page range: 1 - 13
Published on: May 21, 2026
Published by: Transylvanian Museum Society
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Related subjects:
© 2026 Johanna-Irma Lőrinczi, Enikő Nemes-Nagy, Róbert Nemes-Nagy, Maria-Gabriela Rezmüves, Mariana Cornelia Tilinca, published by Transylvanian Museum Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.